Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt turns negative

Q2 FY2026 net debt was -$119.41M, compared with $28.83M a year earlier.

Context

  • Net debt amounted to 15.1% of total assets at the end of Q2 FY2026, up 9.3 pp from a year earlier.
  • Net debt increased in 1 of the last 3 fiscal years.

What to watch

Whether net debt keeps falling in the next quarterly balance sheet after a -514.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$119.41M-532.1% QoQ
Last fiscal yearDec 2025
-$5.4M-32.9% YoY
Year agoJun 2025
$28.83M-514.2% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-514.2%——
1 year-32.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(5.4M) USD
Year-over-year change
-32.9%

Net Debt vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's Jun 2026 net debt of -$119.41M is the 8th highest of the 10 companies compared; the peer median is -$27.28M.
  • Its year-over-year change of -514.2% is the lowest of 8, against a peer median of -0.9%.
  • Net debt amounts to 15.1% of total assets for AUPH, versus a peer median of 13.4%.
AUPH Competitors Peer median
Net Debt for AUPH and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BHVNBiohaven Ltd.Jun 2026$59M -53.1%—15.9%
VERAVera Therapeutics, Inc.Jun 2026$26.35M -7.3%—4.9%
ELDNEledon Pharmaceuticals, Inc.Mar 2026-$5.6M +26.5%—3.8%
ACRSAclaris Therapeutics, Inc.Mar 2026-$26.68M +4.3%—13.4%
ALMSAlumis Inc. Common StockJun 2026-$27.28M +75.9%—4.9%
ATTOAttovia Therapeutics, Inc.Jun 2026-$28.5M ——22.2%
EVMNEvommune, Inc.Mar 2026-$39.2M -120.9%—12.2%
AUPHAurinia Pharmaceuticals Inc.Jun 2026-$119.41M -514.2%—15.1%
MLTXMoonLake ImmunotherapeuticsMar 2026-$197.69M -0.9%—49.4%
TRAXFirst Tracks Biotherapeutics IncMar 2026-$248.47M ——85.5%
Peer median (excluding AUPH) -$27.28M-0.9%—13.4%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents231.9M94.17M48.88M83.43M80.21M
Short-term Investments234.18M295.22M301.61M275.04M317.78M
Net Receivables15.41M13.48M24.09M36.54M41.45M
Inventory19.33M24.75M39.71M39.23M45.69M
Other Current Assets796K1.33M1.03M1.13M1.08M
Total Current Assets513.32M442.54M424.8M446.6M491.97M
Property, Plant & Equipment (Net)9.8M8.56M116.57M98.87M79.57M
Goodwill00000
Intangible Assets8.4M6.43M4.98M4.36M3.76M
Long-term Investments00201K00
Tax Assets0000176.19M
Other Non-current Assets11.84M13.34M1.52M823K93K
Total Non-current Assets30.04M28.32M123.26M104.05M259.62M
Total Assets543.37M470.86M548.06M550.65M751.59M
Account Payables3.88M3.09M4.33M5.19M3.31M
Short-term Debt00000
Tax Payables814K625K667K00
Deferred Revenue190K3.15M4.81M11M3.72M
Other Current Liabilities4.45M2.03M1.59M1.53M2.48M
Total Current Liabilities40.65M46.11M77.19M97.76M93.72M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)000012.65M
Other Non-current Liabilities15.95M12.17M10.91M11.11M6.66M
Total Non-current Liabilities23.63M19.32M92.92M75.4M76.53M
Total Liabilities64.28M65.43M170.11M173.17M170.26M
Common Stock1.18B1.19B1.2B1.19B1.12B
Retained Earnings(756.12M)(864.3M)(942.32M)(936.57M)(649.37M)
Accumulated OCI(852K)(1.06M)(730K)(647K)(599K)
Other Stockholders Equity00000
Minority Interest00000
Total Equity479.09M405.44M377.95M377.48M581.33M
Total Debt8.74M8.09M97.61M79.37M74.81M
Net Debt(223.16M)(86.08M)48.73M(4.06M)(5.4M)

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.